These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 35863944)
1. Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process. Oehrlein EM; Schoch S; Burcu M; McBeth JF; Bright J; Pashos CL; Willke R; Love TR; Mattingly TJ; Perfetto EM; Value Health; 2023 Jan; 26(1):28-38. PubMed ID: 35863944 [TBL] [Abstract][Full Text] [Related]
2. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430 [TBL] [Abstract][Full Text] [Related]
3. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966 [TBL] [Abstract][Full Text] [Related]
4. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229 [TBL] [Abstract][Full Text] [Related]
5. Enhancing Patient Centricity of Real-World Data Research: An Exploratory Analysis Using the Patient Experience Mapping Toolbox. Oehrlein EM; Burcu M; Schoch S; Gressler LE Value Health; 2023 Jan; 26(1):10-17. PubMed ID: 36494301 [TBL] [Abstract][Full Text] [Related]
6. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243 [TBL] [Abstract][Full Text] [Related]
7. Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings. Sun F; Bedenkov A; Liu BC; Yang J; Xu JF; Ji L; Zhou M; Zhang S; Li X; Song Y; Chen P; Moreno C Pharmaceut Med; 2024 May; 38(3):157-166. PubMed ID: 38573457 [TBL] [Abstract][Full Text] [Related]
8. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea. Lee H; Ahn HS; Kwon S; Kang HY; Han E Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484 [TBL] [Abstract][Full Text] [Related]
9. HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force. Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ Value Health; 2022 Oct; 25(10):1663-1672. PubMed ID: 36241338 [TBL] [Abstract][Full Text] [Related]
10. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design. Dagenais S; Russo L; Madsen A; Webster J; Becnel L Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524 [TBL] [Abstract][Full Text] [Related]
11. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force. Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):44-55. PubMed ID: 36215113 [TBL] [Abstract][Full Text] [Related]
12. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews. Polisena J; Jayaraman G Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916 [TBL] [Abstract][Full Text] [Related]
13. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678 [TBL] [Abstract][Full Text] [Related]
14. Tactical Considerations for Designing Real-World Studies: Fit-for-Purpose Designs That Bridge Research and Practice. Dreyer NA; Mack CD Pragmat Obs Res; 2023; 14():101-110. PubMed ID: 37786592 [TBL] [Abstract][Full Text] [Related]
15. Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study. Kim MJ; Kim HJ; Kang D; Ahn HK; Shin SY; Park S; Cho J; Park YH J Med Internet Res; 2023 Mar; 25():e43359. PubMed ID: 36951923 [TBL] [Abstract][Full Text] [Related]
16. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia. Webster J; Smith BD Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609 [TBL] [Abstract][Full Text] [Related]
17. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements. Sievers H; Joos A; Hiligsmann M Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423 [TBL] [Abstract][Full Text] [Related]
18. What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward. Kc S; Lin LW; Bayani DBS; Zemlyanska Y; Adler A; Ahn J; Chan K; Choiphel D; Genuino-Marfori AJ; Kearney B; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Akmal Shafie A; Sui B; Suwantika A; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Teerawattananon Y; Wee HL Int J Health Policy Manag; 2023; 12():6858. PubMed ID: 37579427 [TBL] [Abstract][Full Text] [Related]
19. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group. Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365 [TBL] [Abstract][Full Text] [Related]
20. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions. Wu J; Wang C; Toh S; Pisa FE; Bauer L Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]